Tranexamic Acid as an Intervention in Placenta Previa

• Status: Recruiting
• Trial end date: 2023-12-02
• Target enrollment: 0
• Participant gender: Female

Summary

Antepartum hemorrhage (APH) due to placenta previa is an important cause of worldwide perinatal mortality and maternal morbidity in pregnant women

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hawler Medical University
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Pregnant women 24 weeks gestation and more presented with vaginal bleeding soaked the underwear or required a pad; the bleeding is due to placenta previa, those who are stable hemodynamically; and accepted to participate in the trial

Exclusion Criteria:

• women who had hypersensitivity to tranexamic acid and those with acquired defective color vision; women with a history of venous thromboembolism; having pre-existing medical conditions that could affect pregnancy outcomes (diabetes mellitus, hypertension, renal disease); smokers; and those who refused to participate in the trial